Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Original Medicare covers your doctor bills after the deductible, but the 20% coinsurance has no cap. As costs rise, r...
Retirees are increasingly aiming for dependable cash flow without depleting principal. A $850,000 portfolio that quie...
A new income strategy is gaining traction among retirees and advisers: a retirement portfolio that forks into dual in...
The typical 60-year-old has roughly $246,500 in retirement savings, translating to about three years of expenses. Exp...
AppLovin is rebounding as AI ad-tech momentum returns, with analysts modeling upside to $600+ as AXON 2 expands and b...
A 50-year-old handwritten letter reappears, offering a timeless view on accountability in homebuilding and how borrow...
Amazon’s Q1 2026 results show AWS posting rapid growth amid a surge in AI demand. With AI revenue above $15B and a $2...
A circulating research note questions whether CoreWeave’s backlog is larger than investors expect, potentially signal...
Two consumer-staple giants posted results that intensify the dividend comparison between P&G and Colgate-Palmolive, a...
Politician Vance argues households are nominally richer by about $1,000, but economists say inflation has eaten into ...
Rocket Lab stock remains volatile but disciplined investors see a path to a $150 milestone by 2027 as backlog grows a...